P01CA281850

Understanding integration in oncology care and association with quality and outcomes - Project summary/abstract: Overall program project

This program project seeks to understand features of care integration in oncology that are associated with higher-quality care delivery and better outcomes for individuals with cancer.

Mergers and acquisitions (a form of structural integration) among care delivery organizations have increased substantially in the past decade, particularly in oncology.

Yet, such ownership changes are only one form of structural integration; structural features such as co-location, referral networks, and geographic reach also influence care delivery.

Moreover, other forms of integration, including functional, normative, interpersonal, and process integration, are also important for organizations to provide integrated care.

Structural integration via ownership changes is unlikely to lead directly to better care delivery on its own.

Learning how organizations engage in various forms of integration is critical to understanding how different types of integration influence care.

In this program project, we propose a novel research effort with four interrelated projects reflecting different types of organizations that deliver cancer care.

The organizations include health systems, independent oncology practices, post-acute care and hospice entities, and specialty pharmacies.

Project teams will collect primary data from case studies and surveys and use administrative data from public and commercial insurers to explore the following aims:

Aim 1. Using case studies, adapt an existing conceptual framework and describe key forms of care integration beyond structure (i.e., functional, normative, interpersonal, process) for oncology care that are most relevant for integrated patient care experiences across settings and across the cancer continuum.

Identify mechanisms through which forms of integration may produce integrated patient care and better and more equitable (i.e., narrowing gaps in receipt of high-quality care for marginalized groups) outcomes.

Aim 2. Measure and compare oncology care integration across settings and assess how these key forms of integration are associated with one another.

Assess how structural features, practice factors (e.g., proportion marginalized patients), and market factors relate to non-structural forms of integration (functional, normative, interpersonal, and process).

Aim 3. Assess the association of key forms of integration with utilization, spending, and high-quality and equitable care within and across care settings, including health care systems, independent oncology practices, post-acute care and hospice, and specialty pharmacies, and assess mechanisms through which care integration improves or worsens overall outcomes and receipt of equitable care for marginalized subgroups based on race and ethnicity, residence in rural areas, and socioeconomically deprived areas.

Defining and assessing how health care organizations integrate oncology care for patients with cancer and understanding how integration is associated with key outcomes of cancer treatment will inform policies and practices that can drive improvement in patient outcomes and patient, clinician, and staff experiences.

President And Fellows Of Harvard College

TO IDENTIFY CANCER RISKS AND RISK REDUCTION STRATEGIES, TO IDENTIFY FACTORS THAT CAUSE CANCER IN HUMANS, AND TO DISCOVER AND DEVELOP MECHANISMS FOR CANCER PREVENTION AND PREVENTIVE INTERVENTIONS IN HUMANS. RESEARCH PROGRAMS INCLUDE: (1) CHEMICAL, PHYSICAL AND MOLECULAR CARCINOGENESIS, (2) SCREENING, EARLY DETECTION AND RISK ASSESSMENT, INCLUDING BIOMARKER DISCOVERY, DEVELOPMENT AND VALIDATION, (3) EPIDEMIOLOGY, (4) NUTRITION AND BIOACTIVE FOOD COMPONENTS, (5) IMMUNOLOGY AND VACCINES, (6) FIELD STUDIES AND STATISTICS, (7) CANCER CHEMOPREVENTION AND INTERCEPTION, (8) PRE-CLINICAL AND CLINICAL AGENT DEVELOPMENT, (9) ORGAN SITE STUDIES AND CLINICAL TRIALS, (10) HEALTH-RELATED QUALITY OF LIFE AND PATIENT-CENTERED OUTCOMES, AND (11) SUPPORTIVE CARE AND MANAGEMENT OF SYMPTOMS AND TOXICITIES. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO STIMULATE TECHNICAL INNOVATION, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, AND FOSTER PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS.

93.393 - Cancer Cause and Prevention Research

National Cancer Institute (NCI) [HHS - NIH]

Boston, Massachusetts 021155821 United States

Single Zip Code

National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional) (PAR-23-059)

Amendment Since initial award the total obligations have increased 104% from $2,282,687 to $4,646,365.